Evidence map›Paper›PMID 39229537›Full record

ArticleHeliyon2024

Chong Ma, Jingyi Yin, Xiao Feng, Xin Wang, Xiaodie Cao, Chen Zhang, Rongjie Cui, Jingru Wei, Xu He, Yan Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chong MaDepartment of Pathophysiology, School of Basic Medicine, Kunming University of Science and Technology, Kunming, China.
Jingyi YinDepartment of Pathophysiology, School of Basic Medicine, Kunming University of Science and Technology, Kunming, China.
Xiao FengDepartment of Pathophysiology, School of Basic Medicine, Kunming University of Science and Technology, Kunming, China.
Xin WangDepartment of Pathophysiology, School of Basic Medicine, Kunming University of Science and Technology, Kunming, China.
Xiaodie CaoDepartment of Pathophysiology, School of Basic Medicine, Kunming University of Science and Technology, Kunming, China.
Chen ZhangDepartment of Pathophysiology, School of Basic Medicine, Kunming University of Science and Technology, Kunming, China.
Rongjie CuiDepartment of Pathophysiology, School of Basic Medicine, Kunming University of Science and Technology, Kunming, China.
Jingru WeiDepartment of Pathophysiology, School of Basic Medicine, Kunming University of Science and Technology, Kunming, China.
Xu HeThe First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Yan LiThe First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Li ChenDepartment of Pathophysiology, School of Basic Medicine, Kunming University of Science and Technology, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is associated with high mortality and morbidity rates. Despite major progress of treatment of NSCLC over the past few decades, the prognosis of advanced NSCLC is poor, with 5-year survival rates ranging from 2 % to 13 %.

Indexed as

AktApoptosisBelamcanda chinensis extractMAPKProliferationRafRasThe non-small cell lung cancer

Identifiers

PMID39229537
PMCPMC11369428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.